Business · 1 sources covering this

AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

CNBCLean R·32m ago
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
Read at CNBC →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/0ba082f2fb4d9cccdb1d35be546840ba50dd45b2"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes"></iframe>

AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

How 1 sources are covering this

AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

More from Business

Property Play: Here’s where rental demand is heading and what it means for future home sales

Oil Climbs Toward $100 a Barrel Following Houthi Attacks

China’s Surging Exports Loom Over Trump’s Talks With Xi

The Economic Fallout From a Potential Return to $100 Oil

Reader

Trust & legal

Across the network